Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of temozolomide was based on a Phase III trial that demonstrated a statistically significant survival benefit in combination with radiotherapy versus radiotherapy alone. Temodar also received full approval for its original indication of anaplastic astrocytoma.
You may also be interested in...
Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says
Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme
Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says
Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme
Avastin sBLA Clears Advisory Committee, Faces Quality of Life Hurdle
Accelerated approval for glioblastoma multiforme can be based on objective response rate, panel tells FDA.